எரிஸ் ஆயுள் அறிவியல் லிமிடெட் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Riding on some of its top brands in the chronic superspecialty segment, formulations manufacturing company Eris Lifesciences Ltd has posted a 21 per cent growth in its consolidated profit after tax (PAT) at Rs 68.25 crore for the quarter ended March 31, 2021. The company had posted a PAT of Rs 56.27 crore for Q4 of previous fiscal 2019-20. Eris consolidated total income for the fourth quarter of FY 2020-21 grew by 13 per cent to stand at Rs 280.42 crore, up from Rs 247.5 crore of the corresponding quarter last year. In a year full of multiple disruptions, Eris Lifesciences clocked a 15 per cent growth in MR productivity and grew by 6.2 per cent year-on-year (YoY) in FY21, outperforming by 2x the covered market which grew at 2.9 per cent YoY, making it the third consecutive year of Eris outperforming the covered market and the Indian Pharmaceutical Market (IPM).

Amit bakshiEris lifesciences ltdEris lifesciencesIndian pharmaceutical marketExecutive directorChief operating officerManaging directorHealthcare sectorHealthcare firmsHealthcare companiesHealthcare stocksHealthcare startupsஅமித் பக்ஷிஎரிஸ் ஆயுள் அறிவியல் லிமிடெட்எரிஸ் ஆயுள் அறிவியல்இந்தியன் மருந்து சந்தை